Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 20/20 | 1.00 |
| ▸ | HTR2B | P41595 | 20/20 | 1.00 |
| ▸ | HTR2A | P28223 | 15/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7540136 | 0.87 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL7540345 | 0.82 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL3886777 | 0.81 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL8529483 | 0.75 | HTR2C (0.76) | HTR2CHTR2A | |
| SCHEMBL10197543 | 0.75 | NPC1 (0.70) | HTR2CHTR2BHTR2A | |
| SCHEMBL4523961 | 0.74 | HTR2C (0.58) | HTR2CHTR2BHTR2A | |
| SCHEMBL8116621 | 0.73 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL8132984 | 0.72 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL8118145 | 0.70 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL7539295 | 0.70 | HTR2C (0.57) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | SMITHKLINE BEECHAM P.L.C. | 2002-03-21 | — | — | US | claimed |
| US-6313145-B1 | FOR THERAPY OF ANXIETY AND/OR DEPRESSION | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-06 | — | — | US | claimed |
| EP-0912556-B1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-10-04 | — | — | EP | claimed |
| EP-0912556-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | claimed |
| WO-1997048700-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | claimed |
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | SMITHKLINE BEECHAM P.L.C. | 2002-03-21 | — | — | US | disclosed |
| US-6313145-B1 | FOR THERAPY OF ANXIETY AND/OR DEPRESSION | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-06 | — | — | US | disclosed |
| EP-0912556-B1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-10-04 | — | — | EP | disclosed |
| EP-0912556-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997048700-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | HTR2C, HTR1A, HTR1D | HTR2C 1/4885HTR2B 17/4885HTR2A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.